Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piet Gros

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
Science (New York, N.Y.)|February 17, 2018
Structures of C1-IgG1 provide insights into how danger pattern recognition activates complementDeniz Ugurlar, Stuart C Howes, Bart-Jan de Kreuk, et al.
The EMBO Journal|March 26, 2016
Regulators of complement activity mediate inhibitory mechanisms through a common C3b-binding modeFederico Forneris, Jin Wu, Xiaoguang Xue, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 16, 2022
Multifaceted Activities of Seven Nanobodies against Complement C4bKarla I De la O Becerra, Wout Oosterheert, Ramon M van den Bos, et al.
The New England Journal of Medicine|May 12, 2006
Influence of donor C3 allotype on late renal-transplantation outcomeKatherine M Brown, Elli Kondeatis, Robert W Vaughan, et al.
The Journal of Biological Chemistry|June 25, 2023
Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodiesEva M Struijf, Karla I De la O Becerra, Maartje Ruyken, et al.
The FEBS Journal|March 18, 2020
Site-specific functionality and tryptophan mimicry of lipidation in tetraspanin CD9Viviana Neviani, Sjoerd van Deventer, Tobias P Wörner, et al.
European Journal of Human Genetics : EJHG|June 19, 2014
Heterozygous germline mutations in A2ML1 are associated with a disorder clinically related to Noonan syndromeLisenka E L M Vissers, Monica Bonetti, Jeroen Paardekooper Overman, et al.
Nature Immunology|October 13, 2019
Author Correction: 'Stealth' corporate innovation: an emerging threat for therapeutic drug developmentDimitrios C Mastellos, Anna M Blom, E Sander Connolly, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 22, 2021
C1q binding to surface-bound IgG is stabilized by C1r<sub>2</sub>s<sub>2</sub> proteasesSeline A Zwarthoff, Kevin Widmer, Annemarie Kuipers, et al.
Nature Immunology|September 29, 2019
'Stealth' corporate innovation: an emerging threat for therapeutic drug developmentDimitrios C Mastellos, Anna M Blom, E Sander Connolly, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
Science (New York, N.Y.)|February 17, 2018
Structures of C1-IgG1 provide insights into how danger pattern recognition activates complementDeniz Ugurlar, Stuart C Howes, Bart-Jan de Kreuk, et al.
The EMBO Journal|March 26, 2016
Regulators of complement activity mediate inhibitory mechanisms through a common C3b-binding modeFederico Forneris, Jin Wu, Xiaoguang Xue, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 16, 2022
Multifaceted Activities of Seven Nanobodies against Complement C4bKarla I De la O Becerra, Wout Oosterheert, Ramon M van den Bos, et al.
The New England Journal of Medicine|May 12, 2006
Influence of donor C3 allotype on late renal-transplantation outcomeKatherine M Brown, Elli Kondeatis, Robert W Vaughan, et al.
The Journal of Biological Chemistry|June 25, 2023
Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodiesEva M Struijf, Karla I De la O Becerra, Maartje Ruyken, et al.
The FEBS Journal|March 18, 2020
Site-specific functionality and tryptophan mimicry of lipidation in tetraspanin CD9Viviana Neviani, Sjoerd van Deventer, Tobias P Wörner, et al.
European Journal of Human Genetics : EJHG|June 19, 2014
Heterozygous germline mutations in A2ML1 are associated with a disorder clinically related to Noonan syndromeLisenka E L M Vissers, Monica Bonetti, Jeroen Paardekooper Overman, et al.
Nature Immunology|October 13, 2019
Author Correction: 'Stealth' corporate innovation: an emerging threat for therapeutic drug developmentDimitrios C Mastellos, Anna M Blom, E Sander Connolly, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 22, 2021
C1q binding to surface-bound IgG is stabilized by C1r<sub>2</sub>s<sub>2</sub> proteasesSeline A Zwarthoff, Kevin Widmer, Annemarie Kuipers, et al.
Nature Immunology|September 29, 2019
'Stealth' corporate innovation: an emerging threat for therapeutic drug developmentDimitrios C Mastellos, Anna M Blom, E Sander Connolly, et al.
Pageof 10